Department of Urology/State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital/PLA Medical School, Beijing, China; Department of Urology, The First Hospital of Shijiazhuang, Shijiazhuang, China.
Department of Urology/State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital/PLA Medical School, Beijing, China.
Clin Genitourin Cancer. 2019 Oct;17(5):e1048-e1053. doi: 10.1016/j.clgc.2019.06.007. Epub 2019 Jun 19.
The purpose of this study was to compare perioperative and oncologic outcomes between laparoscopic radical cystectomy (LRC) and robot-assisted radical cystectomy (RARC) for bladder cancer (BCa).
Patients who underwent LRC or RARC with curative intent for BCa between January 2011 and December 2016 were included. Perioperative, pathologic oncologic data were extracted from our database. Disease-free survival, overall survival, and cancer-specific survival were analyzed using Kaplan-Meier survival curves with log-rank tests.
A total of 126 patients underwent LRC and 189 patients underwent RARC during the study period. All the baseline variables were similar between the two groups. Patients undergoing RARC had a significant higher median estimated blood loss (300 mL vs. 200 mL; P = .005), lower rate of 90-day postoperative complications (36.5% vs. 50.0%; P = .017), and higher median direct cost ($15,306 vs. $11,131; P < .001) than LRC. Other perioperative outcomes were similar. No differences were found in pathologic T stage, positive lymph nodes, or positive surgical margin between patients who underwent LRC and RARC. The 5-year disease-free survival, overall survival, and cancer-specific survival rates were 51.9%, 61.0%, and 69.5%, respectively, for all included patients. There were no significant differences in oncologic outcomes between the 2 groups.
Patients with BCa can be safely managed with LRC and RARC by experienced surgeons. RARC was associated with a reduced rate of postoperative complication but also with higher median estimated blood loss, and higher median direct cost. These findings could be used to guide patient counseling, and treatment selection.
本研究旨在比较腹腔镜根治性膀胱切除术(LRC)与机器人辅助根治性膀胱切除术(RARC)治疗膀胱癌(BCa)的围手术期和肿瘤学结果。
纳入 2011 年 1 月至 2016 年 12 月期间接受 LRC 或 RARC 治疗 BCa 的患者。从我们的数据库中提取围手术期、病理肿瘤学数据。使用 Kaplan-Meier 生存曲线和对数秩检验分析无病生存率、总生存率和癌症特异性生存率。
研究期间共 126 例患者行 LRC,189 例患者行 RARC。两组患者的所有基线变量均相似。RARC 组患者的中位估计出血量显著更高(300 毫升 vs. 200 毫升;P =.005),90 天术后并发症发生率较低(36.5% vs. 50.0%;P =.017),中位直接费用较高(15306 美元 vs. 11131 美元;P <.001)。其他围手术期结果相似。LRC 和 RARC 患者的病理 T 分期、阳性淋巴结和阳性手术切缘无差异。所有纳入患者的 5 年无病生存率、总生存率和癌症特异性生存率分别为 51.9%、61.0%和 69.5%。两组患者的肿瘤学结果无显著差异。
经验丰富的外科医生可以安全地为 BCa 患者行 LRC 和 RARC。RARC 术后并发症发生率较低,但估计出血量更高,中位直接费用也更高。这些发现可用于指导患者咨询和治疗选择。